NovaCina, a global contract development and manufacturing organization (CDMO), has today announced the expansion of its facility in Perth, Australia with...
Telix Pharmaceuticals Limited announced an agreement to acquire RLS (USA) Inc. (RLS), America's only Joint Commission-accredited radiopharmacy network sp...
Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024 In patients with any PD-L1 expression (CPS ≥1), efti in co...
Avance Clinical, the award-winning market-leading CRO for biotechs, announced today that 2,000 clinical sites across North America had joined the Avance ...
With great excitement and pride, 360biolabs is thrilled to announce the official opening of its new purpose-built facility, strategically located within ...
Composition-of-matter patent covers the therapeutic use of arsenic salts and metal ions through various routes of administration. Enriched IP portfoli...
Fifty 1 Labs, Inc. , a holding company that operates in the sports supplement, fitness equipment, and health and wellness industries, and All-In-Extracts...
Rznomics Inc., a South Korea based biopharmaceutical company specialized in the development of RNA-based gene therapeutics, announced that it has receive...
Lantheus has agreed to make an initial strategic equity investment of A$7.5 million in Radiopharm Offer price for the shares of A$0.05 represents a 47...
EnGeneIC, a clinical-stage biopharmaceutical company pioneering the development of a First-in-Class targeted nanocell for cancer therapy has today announ...
Avance Clinical, the award-winning Australian and North American market-leading CRO for biotechs has signed a Memorandum of Understanding (MOU) with Juli...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI He...
KCAS Bio continues to deliver against both growth objectives and more integrated customer service offerings. KCAS Bio has partnered with Crux Biolabs, a le...
CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by...
© 2024 Biopharma Boardroom. All Rights Reserved.
